首页> 美国卫生研究院文献>Wiley-Blackwell Online Open >A Randomized Study of the Relative Pharmacokinetics Pharmacodynamics and Safety of Alirocumab a Fully Human Monoclonal Antibody to PCSK9 After Single Subcutaneous Administration at Three Different Injection Sites in Healthy Subjects

【2h】

A Randomized Study of the Relative Pharmacokinetics Pharmacodynamics and Safety of Alirocumab a Fully Human Monoclonal Antibody to PCSK9 After Single Subcutaneous Administration at Three Different Injection Sites in Healthy Subjects

机译：在健康受试者的三个不同注射部位进行单次皮下给药后对PCSK9的全人类单克隆抗体Alirocumab的相对药代动力学药效学和安全性的随机研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

AimsWe investigated the relative pharmacokinetics, pharmacodynamics, and safety of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab following injection at three different sites.

机译：目的我们研究了在三个不同部位注射后前蛋白转化酶枯草杆菌蛋白酶/ kexin 9型（PCSK9）抑制剂alirocumab的相对药代动力学，药效学和安全性。

著录项

期刊名称 Wiley-Blackwell Online Open
作者
Catherine Lunven; Tobias Paehler; Franck Poitiers; Aurélie Brunet; Jacques Rey; Corinne Hanotin; William J Sasiela;
展开▼
作者单位

展开▼
年(卷),期 -1(32),6
年度 -1
页码 297–301
总页数 5
原文格式 PDF
正文语种
中图分类
关键词
Alirocumab Cholesterol Low-density lipoprotein Pharmacodynamics Pharmacokinetics Proprotein convertase subtilisin/kexin type 9;

机译：Alirocumab;胆固醇;低密度脂蛋白;药效学;药代动力学;前蛋白转化酶枯草杆菌蛋白酶/ kexin类型9;

相似文献

外文文献
中文文献

1. A Randomized Study of the Relative Pharmacokinetics, Pharmacodynamics, and Safety of Alirocumab, a Fully Human Monoclonal Antibody to PCSK9, After Single Subcutaneous Administration at Three Different Injection Sites in Healthy Subjects [J] . Lunven Catherine, Paehler Tobias, Poitiers Franck, Cardiovascular therapeutics . 2014,第6期

机译：在健康受试者的三个不同注射部位进行单次皮下给药后，对PCSK9的完全人源单克隆抗体Alirocumab的相对药代动力学，药效学和安全性的随机研究
2. Pharmacokinetics and pharmacodynamics of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, followingsingle-dose administration by subcutaneous and intravenous routes in healthy subjects [J] . ZhangX., GeorgyA., RowellL. International journal of clinical pharmacology and therapeutics . 2013,第6期

机译：ToColizumab的药代动力学和药效学，一种人源化的抗白细胞介素-6受体单克隆抗体，通过皮下和静脉注射治疗的静脉剂量给药
3. Pharmacokinetics and pharmacodynamics of bococizumab, a monoclonal antibody to PCSK9, after single subcutaneous injection at three sites [NCT 02043301] [J] . Wang Ellen Q., Plotka Anna, Salageanu Joanne, Cardiovascular therapeutics . 2017,第5期

机译：Bococizumab的药代动力学和药效学，PCSK9的单克隆抗体，三个位点一次皮下注射后[NCT 02043301]
4. Safety, tolerability, pharmacodynamics and pharmacokinetics following single subcutaneous dosesof a teverelix depot formulation in healthy male volunteers [C] . C. MacLean, F. Larsen, R. Piechatzek, Annual meeting exposition of the Controlled Release Society . 2005

机译：在健康男性志愿者中单次皮下注射Teverelix储库制剂后的安全性，耐受性，药效动力学和药代动力学
5. Pharmacokinetics pharmacodynamics and safety of bococizumab a monoclonal antibody against proprotein convertase subtilisin/kexin type 9 in healthy subjects when administered in co‐mixture with recombinant human hyaluronidase: A phase 1 randomized trial [O] . Almasa Bass, Anna Plotka, Khurshid Mridha, 2018

机译：与重组人透明质酸酶混合使用时bococizumab（抗前蛋白转化酶枯草杆菌蛋白酶/ kexin型9的单克隆抗体）在健康受试者中的药代动力学药效学和安全性：一项1期随机试验
6. A RANDOMIZED STUDY OF THE RELATIVE BIOAVAILABILITY, PHARMACODYNAMICS, AND SAFETY OF ALIROCUMAB, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9, AFTER SINGLE SUBCUTANEOUS ADMINISTRATION AT THREE DIFFERENT INJECTION SITES IN HEALTHY SUBJECTS [O] . Lunven Catherine, Paehler Tobias, Lewanczyk Pascale, 2014

机译：多次连续三个剂量的单次连续给药后，对蛋白质的完全人类单克隆抗体阿洛洛单抗的相对生物利用度，药动学和安全性的随机研究。

A Randomized Study of the Relative Pharmacokinetics Pharmacodynamics and Safety of Alirocumab a Fully Human Monoclonal Antibody to PCSK9 After Single Subcutaneous Administration at Three Different Injection Sites in Healthy Subjects

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅